Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10641699rdf:typepubmed:Citationlld:pubmed
pubmed-article:10641699lifeskim:mentionsumls-concept:C1257890lld:lifeskim
pubmed-article:10641699lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:10641699lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:10641699lifeskim:mentionsumls-concept:C0007789lld:lifeskim
pubmed-article:10641699lifeskim:mentionsumls-concept:C0034656lld:lifeskim
pubmed-article:10641699lifeskim:mentionsumls-concept:C1271100lld:lifeskim
pubmed-article:10641699lifeskim:mentionsumls-concept:C0006050lld:lifeskim
pubmed-article:10641699lifeskim:mentionsumls-concept:C0700323lld:lifeskim
pubmed-article:10641699lifeskim:mentionsumls-concept:C0700702lld:lifeskim
pubmed-article:10641699lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:10641699pubmed:issue1lld:pubmed
pubmed-article:10641699pubmed:dateCreated2000-2-3lld:pubmed
pubmed-article:10641699pubmed:abstractTextIncreased gastrocnemius/soleus muscle tone in children with cerebral palsy may cause an equinus of the ankle. Botulinum toxin type A (BTX), a neuromuscular blocking agent, reduces muscle tone in various neuromuscular disorders. The safety and short-term efficacy of BTX injections were evaluated in a prospective, 3-month, double-blind, randomized clinical trial involving 114 children with cerebral palsy and dynamic equinus foot deformity. Outcome was determined by observational gait analysis, ankle range-of-motion measurements, and quantification of muscle denervation by nerve conduction. Patients in the BTX group demonstrated improved gait function and partial denervation of the injected muscle. No serious adverse events were reported.lld:pubmed
pubmed-article:10641699pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10641699pubmed:languageenglld:pubmed
pubmed-article:10641699pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10641699pubmed:citationSubsetIMlld:pubmed
pubmed-article:10641699pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10641699pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10641699pubmed:statusMEDLINElld:pubmed
pubmed-article:10641699pubmed:issn0271-6798lld:pubmed
pubmed-article:10641699pubmed:authorpubmed-author:WalkerFFlld:pubmed
pubmed-article:10641699pubmed:authorpubmed-author:SmithB PBPlld:pubmed
pubmed-article:10641699pubmed:authorpubmed-author:LeonJ MJMlld:pubmed
pubmed-article:10641699pubmed:authorpubmed-author:KomanL ALAlld:pubmed
pubmed-article:10641699pubmed:authorpubmed-author:MooneyJ...lld:pubmed
pubmed-article:10641699pubmed:issnTypePrintlld:pubmed
pubmed-article:10641699pubmed:volume20lld:pubmed
pubmed-article:10641699pubmed:ownerNLMlld:pubmed
pubmed-article:10641699pubmed:authorsCompleteYlld:pubmed
pubmed-article:10641699pubmed:pagination108-15lld:pubmed
pubmed-article:10641699pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:10641699pubmed:meshHeadingpubmed-meshheading:10641699...lld:pubmed
pubmed-article:10641699pubmed:meshHeadingpubmed-meshheading:10641699...lld:pubmed
pubmed-article:10641699pubmed:meshHeadingpubmed-meshheading:10641699...lld:pubmed
pubmed-article:10641699pubmed:meshHeadingpubmed-meshheading:10641699...lld:pubmed
pubmed-article:10641699pubmed:meshHeadingpubmed-meshheading:10641699...lld:pubmed
pubmed-article:10641699pubmed:meshHeadingpubmed-meshheading:10641699...lld:pubmed
pubmed-article:10641699pubmed:meshHeadingpubmed-meshheading:10641699...lld:pubmed
pubmed-article:10641699pubmed:meshHeadingpubmed-meshheading:10641699...lld:pubmed
pubmed-article:10641699pubmed:meshHeadingpubmed-meshheading:10641699...lld:pubmed
pubmed-article:10641699pubmed:meshHeadingpubmed-meshheading:10641699...lld:pubmed
pubmed-article:10641699pubmed:meshHeadingpubmed-meshheading:10641699...lld:pubmed
pubmed-article:10641699pubmed:meshHeadingpubmed-meshheading:10641699...lld:pubmed
pubmed-article:10641699pubmed:meshHeadingpubmed-meshheading:10641699...lld:pubmed
pubmed-article:10641699pubmed:meshHeadingpubmed-meshheading:10641699...lld:pubmed
pubmed-article:10641699pubmed:meshHeadingpubmed-meshheading:10641699...lld:pubmed
pubmed-article:10641699pubmed:articleTitleBotulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. BOTOX Study Group.lld:pubmed
pubmed-article:10641699pubmed:affiliationDepartment of Orthopaedic Surgery, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157-1070, USA. lakoman@bgsm.edulld:pubmed
pubmed-article:10641699pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10641699pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:10641699pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:10641699pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:10641699pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10641699lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10641699lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10641699lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10641699lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10641699lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10641699lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10641699lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10641699lld:pubmed